MA37998B2 - Anti-cd3 antibodies, bispecific antigen-binding molecules that bind to cd3 and cd20, and their uses - Google Patents
Anti-cd3 antibodies, bispecific antigen-binding molecules that bind to cd3 and cd20, and their usesInfo
- Publication number
- MA37998B2 MA37998B2 MA37998A MA37998A MA37998B2 MA 37998 B2 MA37998 B2 MA 37998B2 MA 37998 A MA37998 A MA 37998A MA 37998 A MA37998 A MA 37998A MA 37998 B2 MA37998 B2 MA 37998B2
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- human
- bind
- binding molecules
- bispecific antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 6
- 102000036639 antigens Human genes 0.000 title abstract 6
- 108091007433 antigens Proteins 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des anticorps qui se lient à cd3 et des procédés d'utilisation de ceux-ci. Selon certains modes de réalisation, les anticorps de l'invention se lient à cd3 humain à affinité élevée et induisent la prolifération de lymphocytes t humains. L'invention comprend des anticorps qui se lient à cd3 et induisent la mort à médiation par des lymphocytes t de cellules tumorales. Selon certains modes de réalisation, la présente invention concerne des molécules de liaison à un antigène bispécifiques, comprenant un premier domaine de liaison à un antigène qui se lie spécifiquement au cd3 humain, et une seconde molécule de liaison à un antigène qui se lie spécifiquement au cd20 humain. Dans certains modes de réalisation, les molécules de liaison à un antigène bispécifiques de la présente invention sont aptes à inhiber la croissance de tumeurs à cellules b exprimant cd20. Les anticorps et molécules de liaison à un antigène bispécifiques de l'invention sont utiles pour le traitement de maladies et de troubles dans lesquels une réponse immunitaire ciblée, régulée à la hausse ou induite, est souhaitée et/ou bénéfique thérapeutiquement. Par exemple, les anticorps de l'invention sont utiles pour le traitement de divers cancers, ainsi que d'autres maladies et troubles associés à cd20.The present invention relates to antibodies that bind to cd3 and methods of use thereof. In some embodiments, the antibodies of the invention bind to high affinity human cd3 and induce proliferation of human t cells. The invention includes antibodies which bind to cd3 and induce T-cell mediated death of tumor cells. According to some embodiments, the present invention provides bispecific antigen-binding molecules, comprising a first antigen-binding domain that specifically binds to human cd3, and a second antigen-binding molecule that specifically binds to human cd3. human cd20. In certain embodiments, the bispecific antigen binding molecules of the present invention are able to inhibit the growth of b-cell tumors expressing cd20. The antibodies and bispecific antigen binding molecules of the invention are useful for the treatment of diseases and disorders in which a targeted, upregulated or induced immune response is desired and / or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers, as well as other diseases and disorders associated with cd20.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261704029P | 2012-09-21 | 2012-09-21 | |
| PCT/US2013/060511 WO2014047231A1 (en) | 2012-09-21 | 2013-09-19 | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37998A1 MA37998A1 (en) | 2017-07-31 |
| MA37998B2 true MA37998B2 (en) | 2020-07-29 |
Family
ID=59745478
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41873A MA41873B2 (en) | 2012-09-21 | 2013-09-19 | Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof |
| MA37998A MA37998B2 (en) | 2012-09-21 | 2013-09-19 | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind to cd3 and cd20, and their uses |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41873A MA41873B2 (en) | 2012-09-21 | 2013-09-19 | Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof |
Country Status (2)
| Country | Link |
|---|---|
| MA (2) | MA41873B2 (en) |
| PY (1) | PY1343212A (en) |
-
2013
- 2013-09-19 MA MA41873A patent/MA41873B2/en unknown
- 2013-09-19 MA MA37998A patent/MA37998B2/en unknown
- 2013-09-20 PY PY201301343212A patent/PY1343212A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA41873A1 (en) | 2018-07-31 |
| MA41873B2 (en) | 2022-04-29 |
| PY1343212A (en) | 2016-12-01 |
| MA37998A1 (en) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42935B1 (en) | Optimized anti-cd3 bispecific antibodies and their uses | |
| MA53168B1 (en) | Bispecific anti-bcma x anti-cd3 antibodies and their uses | |
| JOP20200237A1 (en) | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof | |
| MA49043B1 (en) | STABLE ANTIBODY FORMULATION | |
| EA201990781A9 (en) | ANTI-STEAP2 ANTIBODIES, CONJUGATES ANTIBODY MEDICINES AND BISSPECIFIC ANTIGEN BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND THEIR APPLICATION | |
| JOP20160154B1 (en) | Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof | |
| EA201691858A1 (en) | ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS | |
| MA43327A1 (en) | Peptides and peptide combination for use in immunotherapy against non-small cell lung cancer and other cancers | |
| MA58293B1 (en) | PD-1 BINDING MOLECULES AND METHODS OF USE THEREOF | |
| MA43328A1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| MA43457A1 (en) | Novel peptides, peptide combinations and carriers for use in the immunotherapeutic treatment of various cancers | |
| MA44693A1 (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
| MA40041B1 (en) | Anti-gitr antibodies and methods of use thereof | |
| MA33402B1 (en) | Formulations and methods of targeting the complementary c3b antibody | |
| MA37998B2 (en) | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind to cd3 and cd20, and their uses | |
| MA42523B1 (en) | Anti-psma antibodies, bispecific antigen-binding molecules which bind psma and cd3 and uses thereof | |
| Graham et al. | CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A | |
| EA202190314A1 (en) | BISPECIFIC ANTI-BCMA X ANTI-CD3 ANTIBODIES AND METHODS OF THEIR APPLICATION | |
| MA39751B1 (en) | Antibody compositions for the treatment of tumors | |
| MA46281B1 (en) | Anti-muc16 antibodies (mucin 16) | |
| MA39202B1 (en) | Human antibodies against pd-l1 | |
| MA38159A1 (en) | Isolated antibodies that bind to the bcma antigen used to treat cancers, eg, b-cell cancer and multiple myeloma | |
| MA49604A1 (en) | Human antibodies binding to pd-1 | |
| EA201991227A1 (en) | ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20 | |
| EA201990779A1 (en) | SPECIFIC ANTI-MUC16-CD3 ANTIBODIES AND CONJUGATES ANTI-MUC16-MEDICINE |